ImmusanT Initiates Phase 2 Enrollment for its Lead Therapeutic Vaccine Candidate in Patients With Celiac Disease in Australia and New Zealand

ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, initiated enrollment in Australia and New Zealand for its Phase 2 RESET CeD study assessing the safety, tolerability and efficacy  of its lead therapeutic candidate, Nexvax2®, in patients with celiac disease who carry the immune recognition genes for HLA-DQ2.5.

Read More >

Read More